This statistic depicts the biggest potential biotech and conventional pharmaceutical product launches globally in 2025 and their projected revenues for 2030, as of December 2024. Vertex' Vanza Triple, a cystic fibrosis treatment, is expected to garner some 8.3 billion U.S. dollars in 2030.
* For commercial use only
Basic Account
Starter Account
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
Everything on "Roche" in one document: edited and divided into chapters, including detailed references.
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron
CEO, MindShare Germany
Global overview
Research & development
R&D country comparison
Products
Funding/M&A/IPOs
Focus: U.S. companies
Focus: RNA/mRNA
Further related statistics
* For commercial use only
Basic Account
Starter Account
The statistic on this page is a Premium Statistic and is included in this account.
Professional Account
1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.
